title: Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.
abstract: Adenoviruses are excellent immunotherapeutic agents with a unique ability to prime and boost immune responses. Recombinant adenoviruses cause immunogenic cancer cell death and subsequent release of tumor antigens for antigen presenting cells, resulting in the priming of potent tumor-specific immunity. This effect may be further enhanced by immune-stimulating transgenes expressed by the virus. We report a case of a 38-year-old female with Stage 3 metastatic micropapillary serous carcinoma of the ovary. She was treated in a Phase I study with a granulocyte-macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, Ad5/3-D24-GMCSF (ONCOS-102). The treatment resulted in progressive infiltration of CD8+lymphocytes into the tumor and concomitant systemic induction of several tumor-specific CD8+T-cell populations. The patient was alive at the latest follow up more than 20 months after initiation of the study.
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: L
authors.initials: L
authors.lastname: Vassilev
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Ranki
authors.affiliation: Docrates Cancer Center ; Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Joensuu
authors.affiliation: Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Jäger
authors.affiliation: Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Karbach
authors.affiliation: Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Wahle
authors.affiliation: Docrates Cancer Center ; Helsinki, Finland.
authors.forename: K
authors.initials: K
authors.lastname: Partanen
authors.affiliation: Docrates Cancer Center ; Helsinki, Finland.
authors.forename: K
authors.initials: K
authors.lastname: Kairemo
authors.affiliation: Docrates Cancer Center ; Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Alanko
authors.affiliation: Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland.
authors.forename: R
authors.initials: R
authors.lastname: Turkki
authors.affiliation: Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland.
authors.forename: N
authors.initials: N
authors.lastname: Linder
authors.affiliation: Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Lundin
authors.affiliation: Division of Pathology; HUSLAB and Haartman Institute; Helsinki University Central Hospital ; Helsinki, Finland ; Genome-Scale Biology; Research Programs Unit; University of Helsinki ; Helsinki, Finland.
authors.forename: A
authors.initials: A
authors.lastname: Ristimäki
authors.affiliation: Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Kankainen
authors.affiliation: University of Helsinki and Helsinki University Central Hospital; Cancer Gene Therapy Group ; Helsinki, Finland.
authors.forename: A
authors.initials: A
authors.lastname: Hemminki
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: C
authors.initials: C
authors.lastname: Backman
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: K
authors.initials: K
authors.lastname: Dienel
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: von Euler
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: E
authors.initials: E
authors.lastname: Haavisto
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Hakonen
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Juhila
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Jäderberg
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Priha
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: A
authors.initials: A
authors.lastname: Vuolanto
authors.affiliation: Oncos Therapeutics ; Helsinki, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Pesonen
keywords: Th1 polarization; anti-tumor CD8+ T cell; anti-tumor immunity; in situ vaccine; tumor infiltrating lymphocyte; viral immunotherapy